576-16-9

Basic information

• Product Name: 5-Fluorotryptamine
• Synonyms: 5-FLUOROTRYPTAMINE;AKOS B030092;3-(2-AMINOETHYL)-5-FLUORO-1H-INDOLE;2-(5-FLUORO-1H-INDOL-3-YL)-ETHYLAMINE;RARECHEM AN KA 1417;3-(2-Aminoethyl)-5-fluoro-1H-indole hydrochloride;5-FLUOROTRYPTAMINE,HPLC 98%;2-(5-Fluoro-1H-indole-3-yl)ethanamine
• CAS NO: 576-16-9
• Molecular Formula: C₁₀H₁₁FN₂
• Molecular Weight: 178.21
• Product Categories: Indole/indoline/oxindole;Indole and Indoline;Indoline & Oxindole;Indole
• Mol File: 576-16-9.mol
• Article Data: 17

Chemical Properties

• Melting Point: 273-275 °C
• Boiling Point: 345.959 °C at 760 mmHg
• Flash Point: 163.03 °C
• Appearance: /
• Density: 1.25 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.324
• PKA: 16.37±0.30(Predicted)
• CAS DataBase Reference: 5-Fluorotryptamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluorotryptamine(576-16-9)
• EPA Substance Registry System: 5-Fluorotryptamine(576-16-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 26-36
• Hazardous Substances Data: 576-16-9(Hazardous Substances Data)

Usage

General Description

5-Fluorotryptamine, also known as 5-FT, is a chemical compound that belongs to the family of tryptamines. It is a derivative of serotonin and acts as a 5-HT1A and 5-HT2A receptor agonist. 5-FT has been studied for its potential psychoactive effects, and research suggests that it may have hallucinogenic properties similar to other tryptamine-based compounds. It has also been investigated for its potential therapeutic applications, particularly in the treatment of mood disorders and anxiety. However, further research is needed to fully understand the pharmacological and physiological effects of 5-Fluorotryptamine.

InChI:InChI=1/C10H6F17O4P/c11-3(12,1-2-31-32(28,29)30)4(13,14)5(15,16)6(17,18)7(19,20)8(21,22)9(23,24)10(25,26)27/h1-2H2,(H2,28,29,30)

Synthetic route

5-fluoro-3-(2-nitrovinyl)indole (208645-53-8) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 20℃; for 40h;	92%
With lithium aluminium tetrahydride In tetrahydrofuran Reflux;

(Ε)-5-fluoro-3-(2-nitroethenyl)-1Η-indole (214417-26-2) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 20℃; Inert atmosphere;	76%
With lithium aluminium tetrahydride In tetrahydrofuran for 5h; Ambient temperature;
With lithium aluminium tetrahydride In tetrahydrofuran at 20℃; for 5h;

DL-5-fluorotryptophan (154-08-5) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With pyridoxal 5'-phosphate; aromatic L-amino acid decarboxylase In various solvent(s) at 30℃; for 48h;	41%
With NH4OH-NH4Cl buffer; pyridoxal 5'-phosphate at 30℃; for 0.5h; relative rate of CO2 evolution by aromatic L-amino acid decarboxylase from Micrococcus percitreus;

5-fluoro-3-(2-nitroethyl)-1Η-indole → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Stage #1: 5-fluoro-3-(2-nitroethyl)-1Η-indole With ammonium chloride In tetrahydrofuran; ethanol at 85℃; for 0.166667h; Stage #2: With iron	26.2%

3-(2-amino-ethyl)-5-fluoro-indole-2-carboxylic acid (1512-99-8) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With hydrogenchloride

4-aminobutyrylaldehyde diethylacetal (6346-09-4) + 4-fluorophenylhydrazine (371-14-2) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With zinc(II) chloride at 180℃;

5-fluoro-1H-indole (399-52-0) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: POCl3 / 0.25 h / 20 °C 1.2: CaCO3 / 1,2-dichloro-ethane / 0.5 h / Heating 2.1: 60 percent / ammonium acetate / 1.5 h / Heating 3.1: LiAlH4 / tetrahydrofuran / 5 h / 20 °C View Scheme
Multi-step reaction with 3 steps 1: 1.) POCl3, 2.) CaCO3 / 1.) RT, 15 min, 2.) 1,2-dichloroethane, reflux, 30 min 2: 60 percent / ammonium acetate / 1.5 h / Heating 3: LiAlH4 / tetrahydrofuran / 5 h / Ambient temperature View Scheme
Multi-step reaction with 3 steps 1.1: trichlorophosphate / 1.25 h / 0 - 38 °C 1.2: 0.08 h / 170 °C 2.1: ammonium acetate / 1.5 h / Reflux 3.1: lithium aluminium tetrahydride / tetrahydrofuran / 40 h / 0 - 20 °C View Scheme
Multi-step reaction with 4 steps 1: diethyl ether / 3 h / 0 - 20 °C 2: diethyl ether / 1 h / 20 °C 3: ammonia / water / 24 h / 20 °C 4: lithium aluminium tetrahydride / tetrahydrofuran / 10 h / Reflux View Scheme

5-fluoro-1H-indole-3-carbaldehyde (2338-71-8) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Multi-step reaction with 2 steps 1: 60 percent / ammonium acetate / 1.5 h / Heating 2: LiAlH4 / tetrahydrofuran / 5 h / 20 °C View Scheme
Multi-step reaction with 2 steps 1: 60 percent / ammonium acetate / 1.5 h / Heating 2: LiAlH4 / tetrahydrofuran / 5 h / Ambient temperature View Scheme
Multi-step reaction with 2 steps 1: piperidine; acetic acid / benzene / Reflux 2: lithium aluminium tetrahydride / tetrahydrofuran / Reflux View Scheme
Multi-step reaction with 2 steps 1: ammonium acetate / 1.5 h / Reflux 2: lithium aluminium tetrahydride / tetrahydrofuran / 40 h / 0 - 20 °C View Scheme

piperidine-2,3-dione-3-(4-fluoro-phenylhydrazone) (721-58-4) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Multi-step reaction with 3 steps 1: aqueous HCl; acetic acid 2: aq.-ethanolic KOH 3: aqueous HCl View Scheme

6-fluoro-2,3,4,9-tetrahydro-β-carbolin-1-one (778-73-4) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Multi-step reaction with 2 steps 1: aq.-ethanolic KOH 2: aqueous HCl View Scheme

3-(2-nitroethyl)-6-fluoroindole (937256-55-8) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With hydrazine; nickel In ethanol at 20℃; for 1h;

2-(3-chloropropyl)-1,3-dioxolane (16686-11-6) + 4-fluorophenylhydrazine (371-14-2) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
In ethanol; water at 95℃; for 1h;

C15H19FN2O2 → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Stage #1: C15H19FN2O2 With trifluoroacetic acid In dichloromethane at 25℃; Inert atmosphere; Stage #2: With sodium hydroxide In dichloromethane; water at 25℃; pH=Ca. 12 - Ca. 13; Inert atmosphere;	12.6 mg
With trifluoroacetic acid In dichloromethane at 0 - 25℃; Inert atmosphere;	12.6 mg

C18H13FN2O2 (1198292-69-1) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With hydrazine In ethanol at 20℃; Combinatorial reaction / High throughput screening (HTS);

3-(2-azidoethyl)-5-fluoro-1H-indole (1258297-02-7) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With palladium 10% on activated carbon; hydrogen In ethanol under 3102.97 Torr;

4-chloro-1-hydroxy-1-butanesulfonate sodium (54322-20-2) + 4-fluorophenyhydrazine hydrochloride (823-85-8) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With disodium hydrogenphosphate In ethanol at 70℃; for 6h;

4-fluoroaniline (371-40-4) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: sodium nitrite; hydrogenchloride / water / 1 h / 0 - 5 °C 1.2: 4 h / 80 - 100 °C 2.1: disodium hydrogenphosphate / ethanol / 6 h / 70 °C View Scheme

C10H7FN2O2 → 5-fluorotryptamine (576-16-9)

Conditions	Yield
With lithium aluminium tetrahydride In tetrahydrofuran for 10h; Reflux;

methyl 2-(5-fluoro-1H-indol-3-yl)-2-oxoacetate (408356-39-8) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Multi-step reaction with 2 steps 1: ammonia / water / 24 h / 20 °C 2: lithium aluminium tetrahydride / tetrahydrofuran / 10 h / Reflux View Scheme

2-(5-fluoro-1H-indol-3-yl)-2-oxoacetyl chloride (3828-09-9) → 5-fluorotryptamine (576-16-9)

Conditions	Yield
Multi-step reaction with 3 steps 1: diethyl ether / 1 h / 20 °C 2: ammonia / water / 24 h / 20 °C 3: lithium aluminium tetrahydride / tetrahydrofuran / 10 h / Reflux View Scheme

5-fluorotryptamine (576-16-9) + phenyl chloroformate (1885-14-9) → [2-(5-fluoro-1H-indol-3-yl)-ethyl]-carbamic acid phenyl ester

Conditions	Yield
With pyridine In dichloromethane at 20℃; for 24h; Heating / reflux;	100%

5-fluorotryptamine (576-16-9) + di-tert-butyl dicarbonate (24424-99-5) → tert-butyl N-[2-(5-fluoro-1H-indol-3-yl)ethyl]carbamate (1059175-54-0)

Conditions	Yield
In 1,4-dioxane at 20℃; for 16h;	99%
With triethylamine In tetrahydrofuran at 10℃; for 1h; Inert atmosphere;	83%
With triethylamine In tetrahydrofuran at 10℃; for 1h;	83%

formaldehyd (50-00-0) + 5-fluorotryptamine (576-16-9) → 2-(5-fluoro-1H-indol-3-yl)-N,N-dimethylethanamine (22120-36-1)

Conditions	Yield
With sodium acetate; sodium cyanoborohydride In methanol at 0 - 25℃; for 5h;	97.3%
With sodium cyanoborohydride; acetic acid In methanol for 2h; pH=6.5; Reflux;

5-fluorotryptamine (576-16-9) + salicylaldehyde (90-02-8) → N-(2-hydroxyphenylmethyl)-2-(5-fluoro-3-indolyl)ethylamine

Conditions	Yield
Stage #1: 5-fluorotryptamine; salicylaldehyde In ethanol for 1h; Stage #2: With sodium cyanoborohydride In ethanol	92.5%

5-fluorotryptamine (576-16-9) + 7-(trifluoromethyl)-3,4,5,6-tetrahydro-2H-azepine (1146222-77-6) → 5-(6-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pentan-1-amine

Conditions	Yield
With trifluoroacetic acid In dichloromethane at 20℃; for 168h; Pictet-Spengler Synthesis;	90%

5-fluorotryptamine (576-16-9) + 5-(4-hydroxyphenyl)-2-furancarboxaldehyde (13130-10-4) → 4-[5-({[2-(5-fluoro-1H-indol-3-yl)ethyl]amino}methyl)furan-2-yl]phenol

Conditions	Yield
Stage #1: 5-fluorotryptamine; 5-(4-hydroxyphenyl)-2-furancarboxaldehyde In methanol at 20℃; Molecular sieve; Stage #2: With sodium tetrahydroborate In methanol for 1h; Molecular sieve;	82%

5-fluorotryptamine (576-16-9) + (4-oxo-5-thiophen-2-ylmethylen-2-thioxothiazolidine-3-yl)acetyl chloride → N-[2-(5-fluoro-1H-indol-3-yl)ethyl]-2-[(5Z)-4-oxo-5-thiophen-2-ylmethylen-2-thioxothiazolidin-3-yl]acetamide

Conditions	Yield
With triethylamine In 1,4-dioxane for 0.5h; Heating;	82%

5-fluorotryptamine (576-16-9) + 3-methylsalicylic acid (83-40-9) → N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-2-hydroxy-3-methylbenzamide

Conditions	Yield
Stage #1: 3-methylsalicylic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In acetone at 20℃; for 4h; Stage #2: 5-fluorotryptamine In acetone at 20℃; for 24h;	79.43%

5-fluorotryptamine (576-16-9) + 2-hydroxy-p-toluic acid (50-85-1) → N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-2-hydroxy-4-methylbenzamide

Conditions	Yield
Stage #1: 2-hydroxy-p-toluic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In acetone at 20℃; for 4h; Stage #2: 5-fluorotryptamine In acetone at 20℃; for 24h;	79.43%

5-fluorotryptamine (576-16-9) + salicylic acid (69-72-7) → N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-2-hydroxybenzamide

Conditions	Yield
Stage #1: salicylic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In acetone at 20℃; for 4h; Stage #2: 5-fluorotryptamine In acetone at 20℃; for 24h;	78.23%

5-fluorotryptamine (576-16-9) + di-tert-butyl dicarbonate (24424-99-5) → tert-butyl 3-(2-((tert-butoxycarbonyl)amino)ethyl)-5-fluoro-1H-indole-1-carboxylate

Conditions	Yield
With dmap In dichloromethane at 0 - 20℃;	77%
With dmap In dichloromethane at 0 - 20℃; for 1h;	46%

5-fluorotryptamine (576-16-9) + 4-chlorosalicylic acid (5106-98-9) → 4-chloro-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-2-hydroxybenzamide

Conditions	Yield
Stage #1: 4-chlorosalicylic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In acetone at 20℃; for 4h; Stage #2: 5-fluorotryptamine In acetone at 20℃; for 24h;	75.54%

5-fluorotryptamine (576-16-9) + 5-phenylfuran-2(3H)-one → (11bS)-8-fluoro-11b-phenyl-1,2,5,6,11,11b-hexahydro-3H-indolizino[8,7-b]indol-3-one (1178541-58-6)

Conditions	Yield
With (R)-3,3'-bis(triphenylsilyl)-1,1'-binaphthyl-2,2'-diyl hydrogenphosphate In toluene at 110℃; for 24h; optical yield given as %ee; enantioselective reaction;	73%

5-fluorotryptamine (576-16-9) + 6-(trifluoromethyl)-2,3,4,5-tetrahydropyridine (1146222-76-5) → 4-(6-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)butan-1-amine

Conditions	Yield
With camphor-10-sulfonic acid In water at 130℃; for 14h; Pictet-Spengler Synthesis;	73%

5-fluorotryptamine (576-16-9) + bis(trichloromethyl) carbonate (32315-10-9) + 19-nor-Δ1,3,5(10)-22α-spirostatriene-3-ol (24036-91-7) → (22R,25R)-3β-(5-fluoro-1H-indole-3-ethylamine-carboxylate)-1,3,5(10)-trien-20α-spirostan

Conditions	Yield
Stage #1: bis(trichloromethyl) carbonate; 19-nor-Δ1,3,5(10)-22α-spirostatriene-3-ol With N-ethyl-N,N-diisopropylamine In dichloromethane at 0℃; for 0.5h; Inert atmosphere; Stage #2: 5-fluorotryptamine In dichloromethane at 20℃; for 3h; Inert atmosphere;	73%

5-fluorotryptamine (576-16-9) + 5-bromosalicyclic acid (89-55-4) → 5-bromo-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-2-hydroxybenzamide

Conditions	Yield
Stage #1: 5-bromosalicyclic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In acetone at 20℃; for 4h; Stage #2: 5-fluorotryptamine In acetone at 20℃; for 24h;	71.54%

5-fluorotryptamine (576-16-9) + p-toluenesulfonyl chloride (98-59-9) → N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide (1024493-18-2)

Conditions	Yield
With triethylamine In dichloromethane at 0 - 24℃; for 4h;	71%
With triethylamine In dichloromethane at 0 - 20℃; for 6h;
With triethylamine In dichloromethane at 0℃;
With triethylamine In dichloromethane at 20℃; for 4h;

5-fluorotryptamine (576-16-9) + 5-chloro-2-hydroxybenzoic acid (321-14-2) → 5-chloro-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-2-hydroxybenzamide

Conditions	Yield
Stage #1: 5-chloro-2-hydroxybenzoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In acetone at 20℃; for 4h; Stage #2: 5-fluorotryptamine In acetone at 20℃; for 24h;	70.54%

5-fluorotryptamine (576-16-9) + Methoxyacetyl chloride (38870-89-2) → C13H15FN2O2 (1292285-47-2)

Conditions	Yield
With triethylamine In dichloromethane at 0 - 26℃; for 2h;	68.2%

5-fluorotryptamine (576-16-9) + methyl (2E)-3-(4-formylphenyl)acrylate (7560-50-1, 71093-79-3, 58045-41-3) → 3-[4-[[[2-(5-fluoro-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-(2E)-2-propenoic acid methyl ester

Conditions	Yield
With sodium tris(acetoxy)borohydride In tetrahydrofuran	67%

5-fluorotryptamine (576-16-9) + 1-(3-chloro-5-(trifluoromethyl)pyrid-2-yl)-4-piperidone (339029-35-5) → C21H19ClF4N4

Conditions	Yield
Stage #1: 5-fluorotryptamine; 1-(3-chloro-5-(trifluoromethyl)pyrid-2-yl)-4-piperidone In chloroform for 1h; Molecular sieve; Heating / reflux; Stage #2: With hydrogenchloride; water In chloroform Heating / reflux; Stage #3: With sodium hydrogencarbonate In chloroform; water	67%

5-fluorotryptamine (576-16-9) + 1-((6-bromo-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazole-4-carboxylic acid → 1-((6-bromo-5-methylimidazo[1,2-a]pyridin-2-yl)methyl)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide

Conditions	Yield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 25℃; for 3h;	66%

5-fluorotryptamine (576-16-9) + N,N-dimethyl-4-oxopiperidinium iodide (26822-37-7) → 1-[2-(5-fluoro-1H-indol-3-yl)-ethyl]-piperidin-4-one (151191-79-6)

Conditions	Yield
With potassium carbonate In ethanol	65%

5-fluorotryptamine (576-16-9) + 2-trifluoromethyl-Δ1-pyrroline → 3-(6-fluoro-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propan-1-amine

Conditions	Yield
With camphor-10-sulfonic acid In water at 130℃; for 14h; Pictet-Spengler Synthesis;	63%

but-3-yne-1-sulfonyl chloride + 5-fluorotryptamine (576-16-9) → N-[2-(5-fluoro-1H-indol-3-yl)ethyl]but-3-yne-1-sulfonamide (1452838-28-6)

Conditions	Yield
With triethylamine In dichloromethane at -78℃; Inert atmosphere;	57%

(4-dimethylamino-4-phenyl-cyclohexylmethyl)-carbamic acid phenyl ester (695212-95-4) + 5-fluorotryptamine (576-16-9) → 1-(4-dimethylamino-4-phenyl-cyclohexylmethyl)-3-[2-(5-fluoro-1H-indol-3-yl)-ethyl]-urea

Conditions	Yield
In 1,4-dioxane for 24h; Heating / reflux;	56%
In 1,4-dioxane for 24h; Heating / reflux;

(4,6-dimethylpyrimidin-2-yl)cyanamide (55474-90-3) + 5-fluorotryptamine (576-16-9) → 3-{2-[((4,6-dimethylpyrimidin-2-ylamino)(imino)methyl)amino]ethyl}-5-fluoro-1H-indole

Conditions	Yield
In 1,4-dioxane Heating;	53%

2-methylmorpholine (27550-90-9) + 5-fluorotryptamine (576-16-9) + 4-nitrobenzyl chloroformate (4457-32-3) → N-(p-Nitrobenzyloxycarbonyl)-5-fluorotryptamine (163885-14-1)

Conditions	Yield
In dichloromethane	53%

Upstream product

• 154-08-5 DL-5-fluorotryptophan 
• 1198292-69-1 C₁₈H₁₃FN₂O₂ 
• 6346-09-4 4-aminobutyrylaldehyde diethylacetal 
• 371-14-2 4-fluorophenylhydrazine 
• 3828-09-9 2-(5-fluoro-1H-indol-3-yl)-2-oxoacetyl chloride 
• 408356-39-8 methyl 2-(5-fluoro-1H-indol-3-yl)-2-oxoacetate 
• 371-40-4 4-fluoroaniline 
• 54322-20-2 4-chloro-1-hydroxy-1-butanesulfonate sodium 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 
• 208645-53-8 5-fluoro-3-(2-nitrovinyl)indole 
• 1258297-02-7 3-(2-azidoethyl)-5-fluoro-1H-indole 
• 16686-11-6 2-(3-chloropropyl)-1,3-dioxolane 
• 937256-55-8 3-(2-nitroethyl)-6-fluoroindole 
• 778-73-4 6-fluoro-2,3,4,9-tetrahydro-β-carbolin-1-one 

Downstream Products

• 1357001-61-6 cis-6'-fluoro-2',3',4',9'-tetrahydro-N,N-dimethyl-4-(3-fluorophenyl)spiro[cyclohexane-1,1'(1'H)-pyrido[3,4-b]indole]-4-amine 
• 1357001-75-2 cis-2',3',4',9'-tetrahydro-N,N-dimethyl-6'-fluoro-4-(3-fluorophenyl)-2'-(benzyl)carbonylspiro[cyclohexane-1,1'(1'H)-pyrido[3,4-b]indole]-4-amine 
• 1357001-74-1 cis-(E)-2',3',4',9'-tetrahydro-N,N-dimethyl-6'-fluoro-4-(3-fluorophenyl)-2'-(2-phenylvinyl)carbonylspiro[cyclohexane-1,1'(1'H)-pyrido[3,4-b]indole]-4-amine 
• 1357001-62-7 cis-6'-fluoro-2',3',4',9'-tetrahydro-N,N-dimethyl-4-(phenyl)spiro[cyclohexane-1,1'(1'H)-pyrido[3,4-b]indole]-4-amine 
• 1357001-76-3 cis-(E)-2',3',4',9'-tetrahydro-N,N-dimethyl-6'-fluoro-4-phenyl-2'-(2-phenylvinyl)carbonylspiro[cyclohexane-1,1'(1'H)-pyrido[3,4-b]indole]-4-amine 
• 22120-36-1 N,N-Dimethyl-5-fluoro-1H-indole-3-ethanamine 

Relevant articles and documents

Anti-cancer indole alkaloid compound, preparation method and application thereof

The invention relates to an anti-cancer compound, which is an indole alkaloid series compound and has a general formula (I). Indole alkaloids have a very good inhibitory effect on multiple solid tumors, such as human breast cancer cells, and further have an inhibitory effect on tumor growth. The compound has an inhibitory effect on the growth of cancer cells, but has no inhibitory effect on the growth of normal cells. The compound can be used alone or in combination with other drugs.

Design, synthesis and biological evaluation of tryptamine salicylic acid derivatives as potential antitumor agents

A series of tryptamine salicylic acid derivatives were synthesized and their antiproliferative activity against MGC-803, MCF-7, HepG2, A549 and HeLa cell lines was evaluated. The structure-activity relationship (SAR) study revealed that different substitutions of the C5 and C3′-C5′ positions have certain effects on the anti-proliferation activity. The growth assay revealed that N-[2-(5-bromo-1H-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide (E20) showed the most potent and broad-spectrum anticancer inhibition of all the cell lines evaluated, and was only more potent than 5-Fu for the gastric cancer cell line. Preliminary studies indicated that compound E20 could inhibit colony formation and migration of MGC-803 cells. The flow cytometry (FCM) results showed that compound E20 arrested the cell cycle in the G2/M phase and induced apoptosis of MGC-803 cells in a concentration-dependent manner. In addition, the western blot results showed that E20 can down-regulate the expression of hexokinase 2. Our studies suggest that the framework of N-[2-(5-bromo-1H-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide may be consider as a new type of chemical for designing effective anti-cancer drugs targeting gastric cancer cells.

Chiral anion phase transfer of aryldiazonium cations: An enantioselective synthesis of C3-diazenated pyrroloindolines

Herein is reported the first asymmetric utilization of aryldiazonium cations as a source of electrophilic nitrogen. This is achieved through a chiral anion phase-transfer pyrroloindolinization reaction that forms C3-diazenated pyrroloindolines from simple tryptamines and aryldiazonium tetrafluoroborates. The title compounds are obtained in up to 99% yield and 96% ee. The air- and water-tolerant reaction allows electronic and steric diversity of the aryldiazonium electrophile and the tryptamine core. Live and let diazene: Chiral anion phase transfer of aryldiazonium cations has been utilized to prepare C3-diazenated pyrroloindolines. The air- and water-tolerant reaction allows electronic and steric diversity in the aryldiazonium electrophile and the tryptamine core, with the products being obtained in up to 99% yield and 96% ee (MTBE=methyl tert-butyl ether).